Skip Navigation
About FRD
   For Inventorsfor IndustryFor Entrprenuers
Inventors Introduction
Industry Introduction
Introduction and Resources
Frequently Asked Questions
Available Technologies
Entrepreneurs Introduction
Start-Up Resources
  • Researchers at MUSC have invented a novel double pulsed diffusion magnetic resonance imaging (dMRI) technique, which is referred to as double pulsed diffusional kurtosis imaging (DP-DKI). The technique is essentially an extension of conventional (single-pulsed) DKI to double pulsed field gradient (d-PFG) sequences. This technique leads to a more efficient and practical double pulsed dMRI method that should substantially increase the potential for applications to the clinical assessment of disease by allowing for the quantification of the non-Gaussian diffusion of water within the brain to help characterize tissue microstructure.



  • A new white matter tractography method based on the dMRI technique of diffusional kurtosis imaging (DKI) has been developed. This method, known as DKI fiber tractography (DKI-FT), substantially improves upon the existing technique because of its ability to resolve intersecting fiber bundles. Moreover, since it is also easily implemented on clinical scanners, DKI-FT is an attractive alternative for clinical applications.


  • MUSC inventors have developed an automated, computer-based solution to aid the clinician in analyzing MRI images to detect hippocampal atrophy (HA) that is commonly seen in patients with medial temporal lobe epilepsy (MTLE). Manual morphometry is sensitive to detecting HA, but time-consuming and subject to human error. Automated MRI morphometry can provide rapid, unbiased, and quantitative results via Z-scores to allow for accurate assistance in proper detection of HA and other brain abnormalities. This technology can be utilized to map the locations of the brain in which tissue is abnormally small or large when compared to a normal population. The utilization of Z-scores allows for quantification of the area to assist in clinical diagnosis of abnormal areas of brain tissue.
    The inventors have developed a panel of biomarkers, including various matrix metalloproteinases (MMPs) and tissue inhibitor matrix metalloproteinases (TIMPs), which identifies patients with early-stage changes that are indicative of heart failure. These biomarkers can be detected and measured by performing a simple, point-of-care blood test and provide earlier detection than the current diagnostic tests.
View All TechnologiesFollow Us on LinkedIn!
Harborview Office Tower, 19 Hagood Avenue, Suite 909, Charleston, SC 29403    Ph. 843.876.1900  Fx. 843.876.1905